Src inhibitor
Src inhibitor is a class of inhibitors that targets src kinase family of tyrosine kinases, which is transcribed by proto-oncogenes src genes (abbreviating for sarcome genes) that potentially induced cell of malignant transformation. Because of the crucial position of src gene/kinase in cells, src inhibitors may have prospect to be antineoplastic agents used for pancreatic cancer, breast cancer, stomach cancer et al.[1]
Examples
- KX2-391 is an oral src inhibitor and the first clinical inhibitor with GI50 of 9–60 nM in cancer cell lines.[2]
- Bosutinib has been developed for the treatment of chronic myelogenous leukemia by Pfizer.
- Saracatinib, the first Src inhibitor to show inhibition of the Src pathway in human tumor tissue, has anti-tumor activity alone or in combination with chemotherapeutic agents.[3]
gollark: --remind 0s yes
gollark: For legal reasons.
gollark: Bee lifespans are actually a variable unit.
gollark: ++remind "2024-01-01" topic bridging
gollark: --remind 1m æææææææææa
References
- Rivera-Torres J, José ES (2019). "Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential". FRONTIERS IN PHARMACOLOGY. 10: 1011. doi:10.3389/fphar.2019.01011. PMC 6759511. PMID 31619990.
- Antonarakis ES, Heath EI, Posadas EM, Yu EY, et al. (Apr 2013). "A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer". Cancer Chemother Pharmacol. 71 (4): 883–892. doi:10.1007/s00280-013-2079-z. PMC 3609871. PMID 23314737.
- Nam HJ, et al. "Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer". Mol. Cancer Ther. 12 (1): 16–26. doi:10.1158/1535-7163.MCT-12-0109. PMID 23144237.
- "PP1 is a potent and selective Src inhibitor for Lck/Fyn".
- "biological activity of PP2 in selleck chemicals". Selleck Texas.
- Chan CM, Jing X, Pike LA, Zhou Q, Schweppe RE (2012). "Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis". Clinical Cancer Research. 18 (13): 3580–91. doi:10.1158/1078-0432.CCR-11-3359. PMC 3931551. PMID 22586301.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.